Status:
COMPLETED
Effect of 2nd Gen TKI in CML
Lead Sponsor:
European Society for Blood and Marrow Transplantation
Collaborating Sponsors:
Novartis
Conditions:
Myeloid Leukemia, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
Stem cell transplantation will continue to be a treatment option for patients with chronic myeloid leukaemia, despite the introduction of tyrosine kinase inhibitors. However, many patients will have r...
Detailed Description
Chronic myeloid leukemia (CML) is a clonal disorder characterized by the chromosomal translocation t(9;22) which produces a fusion gene encoding the chimeric oncoprotein, BCR- ABL. This protein harbor...
Eligibility Criteria
Inclusion
- All adult patients with chronic myeloid leukaemia in any phase (chronic, accelerated or blastic) who undergo allogeneic stem cell transplantation between 01/01/2010 and 30/09/2013 and have been previously treated with Nilotinib or Dasatinib, regardless of their response to these drugs.
Exclusion
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2017
Estimated Enrollment :
432 Patients enrolled
Trial Details
Trial ID
NCT02222272
Start Date
January 1 2010
End Date
September 29 2017
Last Update
February 20 2024
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark
2
Helsinki University Central Hospital
Helsinki, Finland
3
University of Freiburg
Freiburg im Breisgau, Germany
4
University of Muenster
Münster, Germany